Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up of WAS gene therapy recipients
2024-512680-31-00Phase 2Authorised
- Sponsor
- Généthon
- Start
- Oct 2014
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of etuvetidigene autotemcel in Wiskott-Aldrich syndrome (WAS), sponsored by Généthon. Planned start Oct 2014; status: authorised.
02
Drugs
etuvetidigene autotemcel
03
Conditions
Wiskott-Aldrich syndrome (WAS)
Beyond the preview
Go deeper on 2024-512680-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512680-31-00.